Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus–Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season —
by from Morbidity and Mortality Weekly Report (MMWR) on (#6K5XQ)
This report describes effectiveness of nirsevimab against respiratory syncytial virus-associated hospitalizations in infants.